BIOGEN STOCK ANALYSIS: Neuroscience Biotech Company

Biogen recently lost 30% of market value in a day, is it time to buy?

Biogen is the fourth largest biotech company in the world after Amgen, Gilead and Celgene. Biogen is focused on neuroscience treating diseases such as Alzheimer, Parkinson disease and multiple sclerosis.

33% of sales come from Tecfidera and 18% from Interferon.

Recent failures in clinical trials of Alzheimer drug Aducanumab is the reason of the recent fall in stock price